

## REMARKS

Upon entry of the present Supplementary Preliminary Amendment, claims 1, 2, 7, 9, 17-30, 44-46, 48, 49, 52, 54, 56, 59, 63, 66, 77, 79, 100, 102, 104 and 111-119 will be pending in the above-identified application. Claims 3-6, 8, 10-16, 31-43, 47, 50, 51, 53, 55, 57, 58, 60-62, 64, 65, 67-76, 78, 80-99, 101, 103 and 105-110 have been canceled without prejudice. Claims 17, 20-26, 30, 44, 49, 63, 66, 77, 79, 100, 102, 104, 111-115 and 119 have been amended for purposes of clarity. No new matter has been introduced by the above-made amendments.

Claims 17 and 20-26 have been amended to depend from claim 1. Claim 21 has been amended to correct a typographical error wherein the term “-Y<sub>y</sub>-” was inadvertently recited instead of “-A-.” Support for this amendment is found in the specification at least at page 82, lines 6-14 (*i.e.*, structure (IIIa)).

Claim 30 has been amended to depend from claim 1 and to incorporate the subject matter of canceled claim 31 (*i.e.*, that -W<sub>w</sub>- can be -valine-citrulline-).

Claim 44 has been amended to replace the term “-Y<sub>y</sub>-W<sub>w</sub>-A” with the term “A’<sub>a</sub>-W<sub>w</sub>-Y<sub>y</sub>-” and to further recite that a is 0 or 1. Support for this amendment is found in the specification at least at page 81, line 12.

Claim 49 has been amended to incorporate the compounds of canceled claims 50 and 51.

Claim 63 has been amended to incorporate the compounds of canceled claims 64 and 65.

Claims 77 and 79 have been amended to depend from claim 1, to replace the ligand “cBR96” with the variable “L,” wherein L can be cBR96, cAC10, an anti-CD40 antibody or an anti-CD20 antibody, and to recite that p can also range from about 3 to about 5 or about 1 to about 3. Support for the recitation of the L groups is found in the specification at least at page 112, lines 2, 3, 5 and 18. Support for the recitation that p can also range from about 3 to about 5 or about 1 to about 3 is found in the specification at least at page 42, line 1 to page 43, line 10.

Claim 100 has been amended to depend from claim 79.

Claim 102 has been amended to depend from claim 77 or 79.

Claim 104 has been amended to depend from claim 77.


Claims 111-115 and 119 have been amended to depend from claims 1, 44, 77, 79, 99, 100, 102 or 104.

Applicants reserve the right to prosecute the subject matter or any canceled or amended claim or any other unclaimed subject matter in one or more continuation, divisional or continuation-in-part applications.

Applicants respectfully request entry of the above-made amendments.

Respectfully submitted,

Date: April 25, 2005

 32,605  
Adriane M. Antler (Reg. No.)

**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017-6702  
(212) 326-3939